Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > # 1 ! on the Top 6 most viewed

<< Previous

Bullboard Posts

Next >>

Comment by lesflicson Jun 11, 2024 12:27pm

83 Views

Post# 36082951

RE:# 1 ! on the Top 6 most viewed

Too many tourists, not enough investors

knoxt wrote:

In Canada’s healthcare sector, Theralase Technologies Inc. (TSXV:TLT, Forum) announced that its lead compound, Ruvidar, has demonstrated effectiveness in inactivating a variety of viruses. This breakthrough was achieved through research conducted at the University of Manitoba in collaboration with the National Microbiology Laboratory.

The findings, published in the peer-reviewed journal Heliyon, revealed that Ruvidar was effective against enveloped and non-enveloped viruses, particularly when light-activated. This discovery could have significant implications for future viral treatments, including potential applications in vaccine development.

In light of recent studies by the CDC highlighting the rising threat of avian influenza, Theralase’s research is particularly timely. The ability of Ruvidar to inactivate the spike protein of the coronavirus without destroying it suggests promising avenues for the development of vaccines.